BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, February 26, 2026
See today's BioWorld
Home
» Firststring Off the (Lab) Bench: Granexin's Phase II Bids Strong
To read the full story,
subscribe
or
sign in
.
Firststring Off the (Lab) Bench: Granexin's Phase II Bids Strong
July 16, 2013
By
Randy Osborne
Firststring Research Inc.'s roll-out of positive, top-line Phase II news in three studies at the International Gap Junction Conference in Charleston, S.C., this week marks the emergence of the company from a low-profile mode.
BioWorld